The approval marks HUMIRA as the only approved biologic treatment option in Canada for pediatric patients from two years of age with chronic non-infectious anterior uveitis who have had inadequate ...

MONTREAL, Feb. 20, 2019 /CNW/ - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that Health Canada has approved HUMIRA® (adalimumab) for the treatment of ...

- If approved, HUMIRA® will be the first biologic treatment option in the European Union for pediatric patients with chronic non-infectious anterior uveitis who have had inadequate response to ...

Bristol-Myers Squibb Company, a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines, has announced the results of AMPLE (Abatacept Versus ...

- The frequency of adverse events was overall similar in both groups; there were numerically fewer discontinuations due to adverse events, serious adverse events, serious infections, and fewer local ...

Humira (adalimumab) is a prescription drug that’s used to treat certain types of arthritis and other inflammation-related diseases. It comes as a liquid solution for injection under your skin. Humira ...

Please provide your email address to receive an email when new articles are posted on . Methotrexate increases the probability of remission with adalimumab or infliximab by 50% in patients with ...

With sarilumab cruising toward a potential FDA approval this fall or earlier, drug developers Sanofi SA and Regeneron Pharmaceuticals Inc. reported that, at week 24, the interleukin-6 receptor ...

Please provide your email address to receive an email when new articles are posted on . Olokizumab demonstrated superiority compared with placebo and non-inferiority compared with adalimumab in ...

Bristol-Myers Squibb has presented two-year data from a head-to-head study which show that its rheumatoid arthritis drug Orencia has comparable safety and efficacy to AbbVie's blockbuster Humira.

Sanofi/Regeneron’s biologic sarilumab has come out on top in a Phase III trial pitting its efficacy in improving the signs and symptoms of rheumatoid arthritis against that of AbbVie’s ...